Rosiglitazone alleviates lipopolysaccharide-induced inflammation in RAW264.7 cells via inhibition of NF-κB and in a PPARγ-dependent manner

Rosiglitazone is a synthetic peroxisome proliferator-activated receptor (PPAR)γ agonist widely used for the treatment of type 2 diabetes. Recent studies have demonstrated that rosiglitazone displays anti-inflammatory effects. The present study aimed to investigate whether rosiglitazone alleviates de...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jing-Ping, Yang, Xiao-Ning, Song, Yang, Zhou, Fei, Liu, Jing-Jing, Hu, Yi-Qun, Chen, Li-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138265/
https://www.ncbi.nlm.nih.gov/pubmed/34055059
http://dx.doi.org/10.3892/etm.2021.10175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138265/
https://www.ncbi.nlm.nih.gov/pubmed/34055059
http://dx.doi.org/10.3892/etm.2021.10175

Ejemplares similares